* Cell Genesys Inc., of Foster City, Calif., said a secondary offeringof 1.48 million shares of its stock owned by early venture investorshas been completed. The company received no proceeds.

* Genentech Inc., of South San Francisco, and Roche Holdings Inc.,of Basel, Switzerland, are changing the form of their agreement madeearlier this month because Genentech's stockholders are not expectedto vote on the matter until after June 30. Terms of the deal areunchanged. (See BioWorld Today, May 2, 1995, p. 1.)

* IBEX Technologies Inc., of Montreal, began a Phase I trial of itslead compound, Neutralase (heparinase I), which is being developedfor the reversal of heparin following bypass surgery.

* XOMA Corp., of Berkeley, Calif., received FDA clearance to starta Phase II trial of Neuprex (rBPI-21), for treatment of trauma patientssuffering complications associated with hemorrhagic trauma. (SeeBioWorld Today, May 11, 1995, p. 1.)

(c) 1997 American Health Consultants. All rights reserved.

No Comments